A Phase 1, First-in-human, Dose-escalation and -expansion Study Of RYZ401, A Novel Radiopharmaceutical Therapy Labeled With Actinium-225, In Patients With Neuroendocrine Tumors And Other Solid Tumors Expressing Somatostatin Receptors

The post A Phase 1, First-in-human, Dose-escalation and -expansion Study Of RYZ401, A Novel Radiopharmaceutical Therapy Labeled With Actinium-225, In Patients With Neuroendocrine Tumors And Other Solid Tumors Expressing Somatostatin Receptors appeared first on RayzeBio .